|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our study demonstrates that gynecologic carcinosarcomas share similarities in their HER2 expression/amplification profiles to endometrial serous carcinomas, which should be taken into account when assessing their HER2 status to ensure appropriate patient selection for potential targeted HER2-based therapies in the future.
|
31477811 |
2020 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
These results support the classification of HER2+ BC into two major subgroups, LH-high and NLH, based on tumour morphology and immune response; LH-high proliferates via scirrhous and/or spiculated growth with a central scar, while the primary proliferation pattern of NLH is based on in situ carcinomas containing comedo necrosis with noticeable TILs and healing.
|
31554015 |
2020 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results underscore, in particular, the relevance of potentially treatable molecular alterations (like ERBB2, BRCA and MSI) in small bowel carcinomas.
|
30717682 |
2019 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The immunophenotypic status of estrogen receptor and Her2 expression of the metastatic carcinomas were all concordant with the primary tumors.
|
30607556 |
2019 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
NST grade 3 and HER2-amplified carcinomas average HER2/CEP17 ratio correlated with an increased number of cells with HER2/CEP17 ≥2.0 (P < 0.014).
|
30113715 |
2019 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Only 2 of those 14 carcinomas (14%) were HER2<sup>+</sup>.
|
29431468 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types.
|
29305518 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
HER2-positive FISH was more frequent in micropapillary carcinomas (12%) and carcinoma with squamous differentiation (11%) than in pure conventional carcinoma (6%).
|
29467478 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Although most are triple (estrogen/progesterone receptor, HER2) negative, these rare tumors are clinicopathologically distinct from other triple negative carcinomas and may be aggressive with worse chemotherapy responses.
|
29946183 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Human Epidermal Growth Factor Receptor 2 Status in Gastric Carcinomas with Distinctive Prevalent Cribriform Component.
|
29670669 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There were 45 deficient MMR (dMMR) cases (8.2%), which showed higher rates of PD-L1 expression compared with MMR-proficient carcinomas (60.0% vs. 35.2%, P = 0.001).HER2 was positive in 66 (12.0%) cases.
|
29673110 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
High expression of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal carcinomas is a predictive biomarker for treatment using HER2-targeted therapeutics (antibodies trastuzumab and pertuzumab, antibody-drug conjugate trastuzumab DM1, and tyrosine kinase inhibitor lapatinib).
|
29977173 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Lastly, we measured HER2 protein expression using PID in the pretreatment biopsies from 34 HER2-positive carcinomas that had undergone neoadjuvant trastuzumab-based chemotherapy.
|
30563489 |
2018 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Double-equivocal carcinomas showed TP53 (6/29, 20%), PIK3CA (3/29, 10%), HER2 (1/29, 3%), and MAP2K4 (1/29, 3%) mutations.
|
29975246 |
2018 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Except for invasive medullary and invasive nonspecific cancers, other invasive carcinomas with a defined subtype were most likely to be diagnosed as luminal B(HER-2-).
|
30568509 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Prophylactic vaccination reduced spontaneous development of mammary carcinomas by 50%-100% in human HER2 transgenic mice and inhibited the growth of HER2-positive tumors implanted in wild-type mice.
|
29399414 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We report 2 cases of exceptional responses of HER2-positive salivary duct carcinomas to dual HER2 blockade and docetaxel combination and their molecular characteristics.
|
30478962 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas: EGFR Amplification is Associated With a Worse Prognosis in Early Stage and Well to Moderately Differentiated Carcinoma.
|
27753660 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HER2 IHC overexpression was associated with higher-grade tumors (p = 0.001), non-organ confined carcinomas (p = 0.017), HER2 amplification (p < 0.00001) and TOP2A amplification (p = 0.016).
|
28755093 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Detection of HER2/neu receptor overexpression and/or amplification is a prerequisite for efficient anti-HER2 treatment of breast and gastric carcinomas.
|
29530054 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We propose that immunohistochemistry for ER, PR, and HER2 is sufficient for patients with low-grade invasive carcinomas and can be used as a surrogate for Oncotype Dx.
|
30230117 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Concomitant expression of ezrin and HER2 predicts distant metastasis and poor prognosis of patients with salivary gland carcinomas.
|
28300573 |
2017 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A Phase 1 study was initiated to evaluate the toxicity profile, maximum tolerated dose (MTD), pharmacokinetics, and antitumor activity of margetuximab in patients with HER2-overexpressing carcinomas.
|
28119295 |
2017 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Carcinomas were subtyped according to hormone receptor (HR) and HER2 status as HR-positive (HR<sup>+</sup>)/HER2<sup>-</sup>, HR<sup>+</sup>/HER2<sup>+</sup>, HR<sup>-</sup>/HER2<sup>+</sup>, and HR<sup>-</sup>/HER2<sup>-</sup>.
|
28576631 |
2017 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, we developed novel DNA aptamers against the extra-cellular domain (ECD) of Her2 protein for detection of Her2-positive carcinomas.
|
28224267 |
2017 |